29 May 2009
Emergence agitation in children after propofol versus halothane anesthesia
Antigona HasaniABCDEFG, Serpil OzgenABFG, Nehat BaftiuBEFGMed Sci Monit 2009; 15(6): CR302-306 :: ID: 869679
Abstract
Background
The administration of anesthetic agents is associated with a high incidence of emergence agitation in children. Halothane and propofol appear to cause much less emergence agitation. The aim of this study was to compare the incidence of emergence agitation in children receiving either propofol or halothane anesthesia for a variety of surgical treatments using the Pediatric Anesthesia Emergence Delirium (PAED) scale.
Material and Method
The subjects were 83 premedicated children aged 1 to 6 years who underwent surgical procedures with propofol (group P, n=41) or with halothane (group H, n=42) anesthesia. The mean dose during maintenance of anesthesia with propofol was 9.0 mg/kg/h or halothane 1.5-2% and fentanyl at a total dose of 5 microg/kg administered during surgery. Recovery time, preoperative anxiety, postoperative pain, and emergence agitation were noted. Adverse effects during and after operation were also recorded.
Results
Group P had a significantly higher proportion of patients who exhibited emergence agitation than group H (29.3% vs. 9.5%, respectively, P<0.05). The PAED scale score in group H was 4 (range: 0-16) and in group P 8 (range: 2-20). The mean recovery time in group P was significantly shorter than in group H (16.1+/-4.3 vs. 20.5+/-5.4 minutes, respectively, P<0.01).
Conclusions
In children, the administration of propofol maintenance anesthesia is associated with a significantly higher incidence of emergence agitation than halothane maintenance anesthesia.
Keywords: Propofol - adverse effects, Halothane - adverse effects, Demography, Child, Delirium - etiology, Anesthetics, Intravenous - adverse effects, Anesthetics, Inhalation - adverse effects, Anesthesia Recovery Period, Anesthesia, Psychomotor Agitation - etiology
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952